PharmaShots | Incisive News in 3 Shots

Subscribe Now

Achondroplasia

BioMarin Report Results of Vosoritide in P-III OLE Study for the Treatment of Children with Achondroplasia at ENDO 2021

BioMarin Report Results of Vosoritide in P-III OLE Study for the Treatment of Children with Achondroplasia at ENDO 2021

March 22, 2021

Biomarin Reports the US FDA's Acceptance of Vosoritide's NDA to Treat Children with Achondroplasia

Biomarin Reports the US FDA's Acceptance of Vosoritide's NDA to Treat Children with Achondroplasia

November 4, 2020

BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia

BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia

August 21, 2020

BioMarin Reports the Submission of MAA to EMA for Vosoritide to Treat Children with Achondroplasia

BioMarin Reports the Submission of MAA to EMA for Vosoritide to Treat Children with Achondroplasia

July 24, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us